{
  "source_documents": {
    "invasive_breast_guideline_pdf": "/mnt/data/breast-invasive-patient.pdf",
    "stage0_dcis_pdf": "/mnt/data/stage_0_breast-patient.pdf",
    "inflammatory_breast_pdf": "/mnt/data/inflammatory-breast-patient.pdf",
    "stage_iv_metastatic_pdf": "/mnt/data/stage_iv_breast-patient.pdf"
  },
  "overview": {
    "purpose": "Structured extraction of NCCN patient guideline recommendations to serve as a rule/knowledge base for personalized breast cancer treatment planning (Stages 0\u2013IV).",
    "notes": "Content extracted and structured from provided NCCN patient guideline PDFs (2025 editions). Use for building rule engine and evidence-mapping."
  },
  "testing_and_baseline": {
    "general_tests": [
      "Medical history and physical exam",
      "Diagnostic mammogram and other imaging as needed",
      "Biopsy with pathology review",
      "Tumor ER/PR status (IHC)",
      "Tumor HER2 status (IHC \u00b1 ISH)",
      "Genetic counseling and testing if at risk (germline BRCA etc.)",
      "Performance status (ECOG/KPS)",
      "Blood tests (CBC, CMP, ALP)",
      "Fertility/pregnancy assessment and counseling",
      "Distress screening and lymphedema baseline screening"
    ],
    "citation": "\ue200filecite\ue202turn3file0\ue202turn3file4\ue201"
  },
  "staging": {
    "stages": {
      "stage_0": "Noninvasive (DCIS) \u2014 Tis, N0, M0",
      "stage_I_II_III": "Invasive (stages 1\u20133) \u2014 local/regional disease",
      "stage_IV": "Metastatic disease (distant spread)"
    },
    "key_points": [
      "Staging uses TNM and receptor (HR/HER2) status.",
      "Clinical stage (cTNM) before treatment; pathologic stage (pTNM) after surgery."
    ],
    "citation": "\ue200filecite\ue202turn3file0\ue201"
  },
  "systemic_therapy_options_by_biomarker": {
    "HR_positive_HER2_negative": {
      "initial_choices": [
        "Endocrine therapy \u00b1 CDK4/6 inhibitor (abemaciclib, palbociclib, ribociclib)",
        "Consider olaparib/talazoparib for germline BRCA mutations",
        "For PIK3CA mutation: alpelisib + fulvestrant (as indicated)"
      ],
      "source": "\ue200filecite\ue202turn3file12\ue202turn3file8\ue201"
    },
    "HER2_positive": {
      "preferred": [
        "Pertuzumab + trastuzumab + docetaxel (preferred)",
        "Pertuzumab + trastuzumab + paclitaxel (preferred)",
        "Trastuzumab-based regimens; 1 year of trastuzumab when indicated"
      ],
      "residual_disease_options": [
        "Ado-trastuzumab emtansine (T-DM1) for residual disease after neoadjuvant therapy",
        "Trastuzumab \u00b1 pertuzumab to complete 1 year if T-DM1 discontinued for toxicity"
      ],
      "source": "\ue200filecite\ue202turn3file11\ue202turn3file17\ue201"
    },
    "triple_negative_breast_cancer_TNBC": {
      "preferred_first_line": [
        "Anthracyclines (doxorubicin) or taxanes (paclitaxel)",
        "For PD-L1 CPS \u226510: pembrolizumab + chemotherapy (albumin-bound paclitaxel / paclitaxel / gemcitabine+carboplatin)",
        "If germline BRCA mutation: consider PARP inhibitor or platinum-based chemo"
      ],
      "residual_disease": [
        "Capecitabine for residual disease after certain neoadjuvant regimens",
        "Sacituzumab govitecan in later lines"
      ],
      "source": "\ue200filecite\ue202turn3file16\ue202turn3file12\ue201"
    }
  },
  "preoperative_neoadjuvant_and_adjuvant": {
    "preoperative_neoadjuvant": [
      "Consider for large tumors, node-positive disease, or cases needing tumor shrinkage before surgery.",
      "Core biopsy, placement of clips, axillary imaging/biopsy recommended before starting."
    ],
    "postoperative_adjuvant": [
      "Adjuvant systemic therapy depends on pathologic stage, nodal status, HR/HER2.",
      "Endocrine therapy typically given for HR+ disease after other systemic therapy as indicated."
    ],
    "citation": "\ue200filecite\ue202turn4file10\ue202turn3file11\ue201"
  },
  "her2_targeted_guides_and_regimens": {
    "guide_summary": [
      "Preferred regimens include paclitaxel + trastuzumab; TCH; TCHP.",
      "If no preoperative therapy or no residual disease, complete up to 1 year trastuzumab; pertuzumab may be added.",
      "If residual disease after preop therapy, consider ado-trastuzumab emtansine (T-DM1) or trastuzumab \u00b1 pertuzumab."
    ],
    "citation": "\ue200filecite\ue202turn3file11\ue202turn4file5\ue201"
  },
  "supportive_care_and_survivorship": {
    "supportive_care": [
      "Manage side effects proactively; report new/worsening symptoms promptly.",
      "Lymphedema monitoring and baseline screening.",
      "Fertility preservation counseling if desired.",
      "Distress screening and psychosocial support."
    ],
    "survivorship": [
      "Provide personalized survivorship care plan listing late effects, follow-up tests, and coordination with primary care."
    ],
    "citation": "\ue200filecite\ue202turn3file18\ue202turn3file3\ue201"
  },
  "decision_rules_structure_for_engine": {
    "input_features_required": [
      "Demographics (age, sex, menopausal status)",
      "Performance status (ECOG/KPS)",
      "Tumor features: size (T), nodes (N), metastasis (M), grade, histology",
      "Receptor status: ER, PR, HER2, PD-L1 (if applicable)",
      "Genetic biomarkers: germline BRCA, PIK3CA, ESR1, AKT1, PTEN, MSI, TMB, NTRK fusions",
      "Prior treatments and response (neoadjuvant response / residual disease)",
      "Comorbidities and contraindications (cardiac, hepatic, pregnancy)",
      "Patient preferences (fertility preservation, goals of care)"
    ],
    "rule_outputs": [
      "Stage-based recommended options (local \u00b1 systemic)",
      "Biomarker-linked targeted therapies",
      "Contraindications and adjusted dosing suggestions",
      "Suggested monitoring and follow-up schedule",
      "Rationale and citation pointer to guideline section"
    ],
    "citation": "\ue200filecite\ue202turn3file0\ue202turn3file12\ue201"
  },
  "examples_of_rule_mappings": {
    "example_1": {
      "if": "HR+ AND HER2- AND postmenopausal AND node_negative",
      "then": "Consider endocrine therapy \u00b1 21-gene assay to decide benefit from adjuvant chemo; consider CDK4/6 if high-risk features",
      "source": "\ue200filecite\ue202turn3file6\ue201"
    },
    "example_2": {
      "if": "HER2+ AND node_positive",
      "then": "Recommend trastuzumab-based chemo + pertuzumab-containing regimen preop or postop as per guide",
      "source": "\ue200filecite\ue202turn3file11\ue201"
    },
    "example_3": {
      "if": "TNBC AND PD-L1 CPS >= 10",
      "then": "Consider pembrolizumab + chemotherapy (as per Guide 6)",
      "source": "\ue200filecite\ue202turn3file16\ue201"
    }
  }
}